Systematic Financial Management’s Charles River Laboratories CRL Stock Holding History

Systematic Financial Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-926	Closed	-$187K	–	252
2023 Q1	$187K	Buy	+926	New	+$210K	0.01%	247
2020 Q3	–	Sell	-1,960	Closed	-$342K	–	295
2020 Q2	$342K	Sell	1,960 -655	-25%	-$105K	0.02%	216
2020 Q1	$330K	Sell	2,615 -1,745	-40%	-$262K	0.02%	285
2019 Q4	$666K	Hold	4,360	–	–	0.03%	236
2019 Q3	$577K	Sell	4,360 -2,339	-35%	-$314K	0.03%	250
2019 Q2	$951K	Sell	6,699 -2,860	-30%	-$388K	0.04%	314
2019 Q1	$1.39M	Sell	9,559 -125	-1%	-$16.4K	0.05%	289
2018 Q4	$1.1M	Sell	9,684 -1,720	-15%	-$215K	0.03%	427
2018 Q3	$1.53M	Sell	11,404 -900	-7%	-$111K	0.04%	322
2018 Q2	$1.38M	Sell	12,304 -435	-3%	-$47K	0.03%	423
2018 Q1	$1.36M	Sell	12,739 -950	-7%	-$102K	0.03%	458
2017 Q4	$1.5M	Sell	13,689 -35	-0.3%	-$3.81K	0.03%	396
2017 Q3	$1.48M	Sell	13,724 -3,445	-20%	-$354K	0.03%	443
2017 Q2	$1.74M	Sell	17,169 -3,445	-17%	-$317K	0.03%	417
2017 Q1	$1.85M	Sell	20,614 -2,160	-9%	-$183K	0.03%	368
2016 Q4	$1.74M	Sell	22,774 -28,730	-56%	-$2.18M	0.03%	454
2016 Q3	$4.29M	Sell	51,504 -484,510	-90%	-$40.6M	0.06%	281
2016 Q2	$44.2M	Sell	536,014 -347,507	-39%	-$28.6M	0.6%	49
2016 Q1	$67.1M	Buy	883,521 +859,877	+3,637%	+$63.7M	0.84%	29
2015 Q4	$1.9M	Sell	23,644 -6,930	-23%	-$500K	0.02%	332
2015 Q3	$1.94M	Sell	30,574 -4,060	-12%	-$292K	0.02%	502
2015 Q2	$2.44M	Buy	34,634 +409	+1%	+$30.3K	0.02%	515
2015 Q1	$2.71M	Sell	34,225 -2,940	-8%	-$217K	0.02%	400
2014 Q4	$2.37M	Sell	37,165 -2,860	-7%	-$179K	0.02%	425
2014 Q3	$2.39M	Buy	40,025 +5,840	+17%	+$334K	0.02%	416
2014 Q2	$1.83M	Buy	34,185 +2,135	+7%	+$117K	0.01%	583
2014 Q1	$1.93M	Sell	32,050 -6,805	-18%	-$397K	0.01%	448
2013 Q4	$2.06M	Buy	38,855 +6,575	+20%	+$330K	0.02%	405
2013 Q3	$1.49M	Sell	32,280 -2,710	-8%	-$124K	0.01%	482
2013 Q2	$1.44M	Buy	+34,990	New	+$1.5M	0.01%	493

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Systematic Financial Management's CRL Position: Q2 2023 in Review

Systematic Financial Management sold out of Charles River Laboratories (CRL) in Q2 2023, closing a stake of 926 shares — an estimated $187K sold.

Systematic Financial Management first reported a position in CRL in Q2 2013 and held it in 30 quarters. The position peaked at $67.1M in Q1 2016. 611 funds tracked by Wall St. Rank hold CRL as of Q2 2023.

Systematic Financial Management reported no remaining Charles River Laboratories position as of Q2 2023 after selling out during the quarter.
Systematic Financial Management sold 926 Charles River Laboratories shares in Q2 2023, an estimated $187K.
Systematic Financial Management first reported a position in Charles River Laboratories in Q2 2013 and held it in 30 quarters.
Systematic Financial Management's Charles River Laboratories position peaked at $67.1M in Q1 2016.
611 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2023.

Based on Systematic Financial Management's 13F filing for Q2 2023, filed 14 Aug 2023.